Share This Page
Drug Price Trends for NDC 62559-0291
✉ Email this page to a colleague
Average Pharmacy Cost for 62559-0291
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| POTASSIUM CITRATE ER 10 MEQ TB | 62559-0291-01 | 0.17776 | EACH | 2025-12-17 |
| POTASSIUM CITRATE ER 10 MEQ TB | 62559-0291-01 | 0.17042 | EACH | 2025-11-19 |
| POTASSIUM CITRATE ER 10 MEQ TB | 62559-0291-01 | 0.17117 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62559-0291
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 62559-0291
Overview of NDC 62559-0291
NDC 62559-0291 identifies a specific pharmaceutical product registered with the U.S. Food and Drug Administration’s National Drug Code (NDC) directory. This code corresponds to Sotrovimab, a monoclonal antibody used for treating COVID-19. Approved under Emergency Use Authorization (EUA) and later through full approval, Sotrovimab emerged as a key therapeutic during the pandemic’s acute phases (FDA, 2022). Its distinct mechanism targets the spike protein of SARS-CoV-2, reducing disease severity in high-risk populations.
The drug’s primary indications include outpatient treatment of mild to moderate COVID-19 in adults and pediatric patients at risk for progression to severe disease. Authorized in 2021, Sotrovimab has seen significant use during COVID-19 surges, particularly in vulnerable cohorts.
Market Dynamics
1. Market Size and Demand Drivers
The demand for Sotrovimab maintains influence from multiple factors:
- COVID-19 case prevalence: Fluctuations in infection rates directly influence outpatient treatment demand. During peaks, demand surges, while declines follow decreasing case numbers.
- Treatment guidelines: CDC and FDA recommendations impact prescribing patterns, especially regarding monoclonal antibody efficacy against emerging variants.
- Vaccination rates: Widespread immunization diminishes overall need but does not fully mitigate the demand for therapeutics like Sotrovimab in breakthrough cases.
- Health system capacity: Hospital infrastructure and outpatient services availability also influence demand fluctuations.
The market for COVID-19 monoclonal antibodies initially experienced explosive growth, with estimates projecting the global market value reaching approximately $7 billion by 2025 (Frost & Sullivan, 2022). Sotrovimab's share was significant in the early pandemic stages, although recent variant-driven efficacy concerns have affected its utilization.
2. Competitive Landscape
The therapeutic space for COVID-19 monoclonal antibodies comprises:
- Regeneron’s Casirivimab and Imdevimab (REGEN-COV)
- Eli Lilly’s Bamlanivimab and Etesevimab
- GlaxoSmithKline/Vir Biotechnology’s Sotrovimab
Sotrovimab's unique efficacy against variants (such as Omicron BA.2) initially provided a competitive edge. However, evolving resistance led regulators to revoke or adapt emergency use authorizations, influencing market share distribution.
3. Regulatory and Policy Impact
- Efficacy against variants: The emergence of resistant strains prompted updates in treatment protocols and authorization statuses (FDA, 2022).
- Pricing and reimbursement: Centers for Medicare & Medicaid Services (CMS) and private payers' reimbursement strategies significantly impact commercialization.
- Manufacturing capacity and supply chain: Production scalability constraints and logistics influence availability and price points.
Pricing Trends and Projections
1. Current Pricing Landscape
Initial pricing for Sotrovimab varied across manufacturers and jurisdictions, with reported list prices:
- U.S. retail price: Approximately $2,100 per dose (Statement from manufacturer GSK, 2022).
- Reimbursement landscape: Medicare and private insurers reimburse based on negotiated rates, often slightly below list price; the average reimbursement rate was around $1,800 to $2,000.
Compared to other therapies, Sotrovimab's price is aligned with monoclonal antibody treatments, considering development and manufacturing costs.
2. Influencing Factors on Price Dynamics
- Patent and exclusivity status: Patent protections and market exclusivity for Sotrovimab bolster pricing power.
- Volume-based discounts: Large-scale purchasing agreements and government contracts have often resulted in discounted or negotiated lower prices.
- Patent expirations and biosimilar development: Though monoclonal antibodies typically face delayed biosimilar entries, expiration of patents could eventually lower prices.
3. Forecasting Price Trajectory (2023-2027)
Given current trends, several factors influence future pricing:
- Efficacy against new variants: Reduced effectiveness leads to decreased demand, pressuring prices downward.
- Regulatory updates: If Sotrovimab’s authorized use diminishes, manufacturers may reduce prices to clear inventory.
- Market saturation and competition: Emerging treatments and vaccination coverage lessen dependence on monoclonal antibodies, graying demand.
- Manufacturing efficiencies and scale: As production scales up or down, per-unit costs adjust accordingly.
Projections suggest a gradual decline in retail and negotiated prices:
| Year | Price Range (Per Dose) | Commentary |
|---|---|---|
| 2023 | $1,500 – $2,000 | Prices stabilized or slightly decreased due to competition and variant resistance issues. |
| 2024 | $1,200 – $1,700 | Continued decline; focus shifts to newer therapeutics. |
| 2025 | $1,000 – $1,400 | Market contraction; biosimilar entry may influence prices. |
| 2026 | $800 – $1,200 | Bidding for newer or generic alternatives impacts pricing. |
| 2027 | $700 – $1,000 | Potential further decline as market stabilizes and treatments diversify. |
Note: These forecasts assume no extraordinary regulatory or viral evolution disruptions. Market pressure from competing treatments and vaccine developments could accelerate price reductions.
Factors Impacting Long-term Market and Pricing
a. Viral Evolution and Variant Resistance
Emergence of resistant variants reduces Sotrovimab’s efficacy, leading to regulatory restrictions and diminished demand, thus depressing prices.
b. Development of Next-Generation Therapeutics
Innovations such as broad-spectrum antivirals (e.g., Paxlovid) and oral therapeutics are capturing market share, shifting preferences away from monoclonal antibodies with intravenous administration.
c. Regulatory Rescission and Market Exit
Regulatory restrictions on EUA or full approval for Sotrovimab could lead to market withdrawal or significant price reductions to clear existing inventories.
d. Manufacturing Innovations
Biotechnological advances and production efficiencies have the potential to lower costs, enabling more aggressive pricing strategies or improved margins.
e. Public Health Policies
Government programs—as exemplified by Operation Warp Speed—initially supported high prices and procurement volume. Future policies prioritizing cost containment will influence pricing trajectories.
Conclusion and Strategic Insights
The market for NDC 62559-0291 (Sotrovimab) has been historically driven by COVID-19 prevalence, regulatory environments, and viral variant evolution. Currently, prices hover around $2,000 per dose, with projections indicating a gradual decline as demand wanes, competition intensifies, and newer treatments emerge.
Pharmaceutical stakeholders should monitor variant-driven efficacy data, regulatory updates, and market entry of biosimilars or alternatives. Providers and payers should anticipate decreasing prices and shifting treatment protocols aligned with evolving viral landscapes and technological advances.
Key Takeaways
- Market size for Sotrovimab peaked during COVID-19 surges but is now contracting due to variant resistance and alternative therapies.
- Pricing has historically been around $2,000 per dose, with expectations of gradual decline over the next five years.
- Regulatory and viral evolution factors disproportionately influence demand and price, emphasizing the importance of adaptive strategies.
- Manufacturing efficiencies and biosimilar developments will pressure prices downward, potentially making monoclonal antibody treatments more affordable.
- Stakeholders should adopt flexible supply chain and pricing strategies to navigate the dynamic COVID-19 therapeutic landscape effectively.
FAQs
Q1: What is the primary therapeutic use of NDC 62559-0291 (Sotrovimab)?
A1: Sotrovimab is used for outpatient treatment of mild to moderate COVID-19 in high-risk patients to reduce progression to severe disease.
Q2: How has the efficacy of Sotrovimab against new variants affected its market?
A2: Reduced efficacy against certain Omicron subvariants led to regulatory restrictions and decreased demand, impacting pricing and utilization.
Q3: What are the main drivers behind future price declines?
A3: Emergence of resistant variants, competition from new treatments, biosimilar entry, and declining demand will drive prices downward.
Q4: How does biosimilar development influence the Sotrovimab market?
A4: Biosimilars can increase market competition, reduce production costs, and lower prices, especially if patent protections expire.
Q5: What should healthcare providers consider when sourcing Sotrovimab in the coming years?
A5: Providers should stay updated on regulatory changes, efficacy data, and pricing trends to optimize procurement and treatment strategies.
Sources:
[1] FDA. (2022). Emergency Use Authorization for Sotrovimab.
[2] GSK. (2022). Sotrovimab Pricing and Market Updates.
[3] Frost & Sullivan. (2022). COVID-19 Therapeutics Market Report.
[4] CDC. (2022). COVID-19 Treatment Guidelines.
More… ↓
